Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

ITbM researchers find new molecules that change circadian rhythm in mammals

A team of chemists and biologists at the Institute of Transformative Bio-Molecules, Nagoya University have succeeded in finding new molecules that change the circadian rhythm in mammals by applying synthetic chemistry methods, which makes use of highly selective metal catalysts.

10 Jun 2015

Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Washington State University Spokane scientists have grown a tiny group of brain cells that can be induced to fall asleep, wake up and even show rebound sleep after "staying up late."

10 Jun 2015

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

9 Jun 2015

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

9 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Non-invasive prenatal testing for Down's syndrome acceptable to parents

Non-invasive prenatal testing (NIPT) for Down's syndrome is feasible, acceptable to parents, and could be introduced into the National Health Service, UK researchers say. The results of a National Institute for Health Research study carried out by the first NHS laboratory to provide NIPT testing will be reported to the annual conference of the European Society of Human Genetics today (Saturday).

8 Jun 2015

University at Albany researcher receives $1.76 million NIH grant to explore role of vitamin D in breast cancer

Each year, about 230,000 new cases of breast cancer are diagnosed in women in the U.S. It remains the third leading cause of death, behind only heart disease and lung cancer. Of the new cases, about 20 percent of women will be diagnosed with "triple negative" breast cancer (TNBC), a deadly form of breast cancer that does not respond to standard treatments such as tamoxifen or aromatase inhibitors.

7 Jun 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

5 Jun 2015

Researchers identify immune system marker that drives therapy-resistant prostate cancer

You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you -- in comparison with other patients -- will actually be helped by the treatment. This is often the situation with prostate cancer, one of the deadliest and most highly prevalent cancers. While hormone therapy can help, patient responses vary widely, and it's still unclear why some types of prostate cancer seem to be resistant to the therapy.

5 Jun 2015

Medical experts call for accurate, standardized estrogen testing methods

Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Griffith student finds success in medical tourism

The world of medical tourism was not one that Dan Donner had ever considered as a potential career path, but today he can be found dividing his time between study at Griffith University and running a flourishing business in Thailand.

5 Jun 2015

Dexcom® announces follow App is now available for Android devices

Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years...

4 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

Scientists uncover why some people more prone to major depression

Scientists are beginning to unwrap the biology behind why some people are more prone to major depression and other psychiatric disorders than others when experiencing stressful life events. The researchers found that cellular activity in response to stress hormone receptor activation differs from individual to individual.

4 Jun 2015

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

The Intellectual Property and Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, recently honored Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

3 Jun 2015

Lower-functioning children with ASD exhibit higher levels of cortisol

Researchers at the Institute for Autism Research at Canisius College have found that functional level appears to play a critical role in the stress levels of children with autism spectrum disorder (ASD). Specifically, lower-functioning children with ASD (LFASD) exhibited significantly higher levels of cortisol, the primary stress hormone in humans, than both high-functioning children with ASD (HFASD) and typical children.

3 Jun 2015

UAB study finds how genetic variation in IIS/TOR molecular network may regulate variation in metabolism

New research from the University of Alabama at Birmingham finds genetic variants that occur in nature and lay the groundwork for future studies of diseases and treatments in humans.

3 Jun 2015

Hormone News and Research

Further Reading

ITbM researchers find new molecules that change circadian rhythm in mammals

Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Study shows how GLP-1 receptor agonists modify the brain's response to food

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Non-invasive prenatal testing for Down's syndrome acceptable to parents

University at Albany researcher receives $1.76 million NIH grant to explore role of vitamin D in breast cancer

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

PALOMA3 supports palbociclib use in advanced breast cancer

Researchers identify immune system marker that drives therapy-resistant prostate cancer

Medical experts call for accurate, standardized estrogen testing methods

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Griffith student finds success in medical tourism

Dexcom® announces follow App is now available for Android devices

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Scientists uncover why some people more prone to major depression

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Lower-functioning children with ASD exhibit higher levels of cortisol

UAB study finds how genetic variation in IIS/TOR molecular network may regulate variation in metabolism

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News